Treatment incidence of and medical utilization for hospitalized subjects with pathologic fractures in Taiwan—Survey of the 2008 National Health Insurance data

Yi-Hui Lee1,2†, Yuan-Nian Hsu3,4, I-Liang Yu3,5, Dinh-Van Phan5, Pesus Chou6, Chien-Lung Chan5† and Nan-Ping Yang3,6*

Abstract

Background: Almost all studies of pathologic fractures have been conducted based on patients with tumors and hospital-based data; however, in the present study, a nationwide epidemiological survey of pathologic fractures in Taiwan was performed and the medical utilization was calculated.

Methods: All claimants of Taiwan’s National Health Insurance (NHI) Program in 2008 were included in the target population of this descriptive cross-sectional study. The registration and inpatient expenditure claims data by admission of all hospitalized subjects of the target population were examined and the concomitant International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes were evaluated and classified into seven major categories of fracture.

Results: A total of 5,244 incident cases of pathologic fracture were identified from the 2008 hospitalized patient claims data. The incidence of pathologic fracture of the humerus, distal radius/ulna, vertebrae, femoral neck, other part of the femur, and tibia/fibula was 0.67, 0.08, 10.58, 1.11, 0.56, and 0.11 per 100,000 people, respectively, and patients with those fractures were hospitalized for 43.9 ± 42.9, 31.1 ± 32.9, 29.4 ± 34.4, 43.3 ± 41.2, 42.4 ± 38.1, and 42.0 ± 32.8 days, respectively, incurring an average medical cost of US$11,049 ± 12,730, US$9,181 ± 12,115, US$6,250 ± 8,021, US$9,619 ± 8,906, US$10,646 ± 11,024, and US$9,403 ± 9,882, respectively. The percentage of patients undergoing bone surgery for pathologic fracture of the humerus, radius/ulna, vertebrae, femoral neck, other part of the femur, and tibia/fibula was 31.2%, 44.4%, 11.3%, 46.5%, 48.4%, and 52.5% respectively.

Conclusions: Comparing Taiwan to other countries, this study observed for Taiwan higher medical utilization and less-aggressive surgical intervention for patients hospitalized with pathologic fractures.

Keywords: Incidence, utilization, pathologic fracture
fractures in the orthopaedic field of the treatment of fragility fractures.

Most pathologic fracture studies have been conducted based on tumour-associated patients and hospital-based data, and no nationwide epidemiological survey of pathologic fractures has been performed to date. This study therefore aimed to perform a nationwide epidemiological survey of pathologic fractures in Taiwan independent of cause and calculate the medical utilization, which could be of use to policymakers in Taiwan in redistributing medical resources and promoting more aggressive treatment.

Methods
Source, security, and quality control of data
Taiwan launched a single-payer NHI Program in 1995, and as of 2007, 22.60 million Taiwanese people of a total population of 22.96 million were enrolled in this program; foreigners in Taiwan are also eligible for inclusion. In order to respond to current and emerging health issues rapidly and effectively, in cooperation with the National Health Insurance Bureau (NHIB), the National Health Research Institute (NHRI) established a nationwide research database, and the NHIB established a uniform system to control the quality of medical services and coding.

The NHRI safeguards the privacy and confidentiality of patients included in the database and routinely transfers health insurance data from the NHIB to enable health researchers to analyse and improve the health of Taiwan’s citizens. The National Health Insurance (NHI) database contains registration files and original claims data for reimbursement, and access to the National Health Insurance Research Database (NHIRD), which was derived from this system by the NHIB and is maintained by the NHRI, is provided to scientists in Taiwan for research purposes.

Data protection and permission
Any data in the NHIRD that could be used to identify patients or care providers, including medical institutions and physicians, are scrambled before being sent to the NHRI for database inclusion, and the data are further scrambled before being released to researchers. Theoretically, it is impossible to query the data alone to identify individuals at any level using this database. The protocol of this study was evaluated by the NHRI, who gave their agreement to the planned analysis of the NHIRD (Application and Agreement Number: 99005). This study was also approved by the Institutional Review Board (IRB) of Taoyuan General Hospital, which has been certified by the Department of Health, Taiwan (IRB Approval Number: TYGH098033).

Data selection and definition of pathologic fractures
All claimants of Taiwan’s NHI Program at any time during 2008 were included in the target population of this descriptive cross-sectional study. In order to investigate the treatment incidence of pathologic fractures among hospitalized subjects of the target population, the registration and claims data of inpatient expenditure by admission were examined and the concomitant ICD-9-CM diagnosis codes were evaluated and classified into seven major categories. Pathologic fracture of the humerus was defined as the diagnosis code 733.11 and pathologic fracture of the distal radius/ulna was coded 733.12. The third category, pathologic fracture of vertebrae, was coded 733.13. Pathologic fractures of the neck of the femur, any other part of the femur, and the tibia/fibula were coded 733.14, 733.15 and 733.16, respectively. The seventh category, pathologic fractures of unspecified or other sites, included all other cases and was coded 733.1, 733.10 or 733.19.

Statistics
The method of back-projection was used to estimate the unobserved past incidences of various pathologic fractures, which are expressed as the proportions of the target population in Taiwan. The independent t-test and Pearson’s chi-square test were used for simple descriptive comparison of differences in the indicators of medical utilization and bony surgery rates between genders.

Results
Treatment incidence of pathologic fractures of various locations and associated metabolic disorders
According to the previously-defined selection criteria, 3,094 subjects who were hospitalized for pathologic fracture in 2008 were identified. Of the 3,094 studied subjects, 5,244 incident cases of various categories of pathologic fracture were identified within one year (i.e., in 2008, Taiwan) (Table 1), which included 3,003 recognized cases of fracture in six major locations and 2,241 almost concomitant with the above but unspecified cases. By dividing the number of cases by the number of beneficiaries of the same age and gender in 2008, the estimated incidence of pathological fracture requiring hospitalization in Taiwan categorized by fracture location was calculated. The treatment incidence of most of the variously-located pathologic fractures increased with age for both genders, and this trend was very obvious for fractures of the vertebrae and femoral neck. In general, the estimated incidence of pathologic fracture in Taiwan was 22.89 per 100,000 people based on the nationwide health insurance hospitalization data, and the individual incidence of fracture of the humerus, distal radius/ulna, vertebrae, femoral neck, other femoral location, and tibia/fibula was 0.67, 0.08, 10.58, 1.11,
0.56, and 0.11 per 100,000 people, respectively. Worthy of note, a high proportion of unspecified or alternatively-located pathologic fractures was noted, the estimated incidence being 9.78 per 100,000 people.

Medical utilization for the various identifiable-located pathologic fractures and concomitant bony surgery

Table 2 shows the average medical utilization for patients hospitalized with identifiable-located pathologic fractures in Taiwan. For humeral pathologic fractures, the average hospital stay was 43.9 ± 42.9 days and the associated direct medical cost was US$11,049 ± 12,730 (currency conversion rate: US$1 = NT$32). For distal radial/ulnar, vertebral, femoral neck, other part of the femur, and tibial/fibular pathologic fractures, patients stayed in hospital for 31.1 ± 32.9, 29.4 ± 34.4, 43.2 ± 41.2, 42.4 ± 38.1 and 42.0 ± 32.8 days, respectively, and the associated direct medical cost was US$9,181 ± 12,114, US$6,250 ± 8,021, US$9,619 ± 8,906, US$10,646 ± 11,024 and US$9,403 ± 9,882, respectively. The differences in medical utilization between genders were also estimated incidence being 9.78 per 100,000 people.

Discussion

The exact incidence of bone metastasis is unknown, but of the estimated 1.2 million new cases of cancer diagnosed annually in the US, more than 50% will eventually demonstrate skeletal metastases [5], and it is estimated that 350,000 people die of bone metastases annually in the US [6]. National prevalence estimates were produced from the 2000-2004 MarketScan databases of the USA, and of 396,200 oncology patients, 18,042 (4.6%) were identified as having bone metastasis. Applying the projection methodology, 5.3% of these patients were projected to have bone metastases [7]. This study revealed that the estimated incidence of treated pathologic fracture is 22.89 per 100,000 people annually in Taiwan. More epidemiological cohort surveys of the oncology registry data in Taiwan are needed in order to compare the cumulative incidence of pathologic fracture with that in other countries.

The incidences of pathologic fractures of some specific locations have rarely been reported. One epidemiological survey of 401 fractures of the shaft of the humerus revealed that 8% of the fractures were pathologic [8]. A retrospective 36-year chart review of all patients with metastatic bone disease admitted to a single tertiary orthopaedic referral centre was conducted, which identified 601 females and 580 males (mean: 60 years) with metastatic bone disease, of the femur (28%) and spine (29%) in the main [9]. In the present study of pathologic fractures in Taiwan requiring hospitalization, the spine was found to be the most common location, followed by parts of the femur and the humeral area. However, a high proportion (42.7%) of cases of pathologic fracture at unspecified sites was noted, and, possibly through some administrative encouragement means provided by the Taiwan’s health insurance authority, the accuracy of coding should be improved to ensure the validity of the data of Taiwan’s health insurance system.
| Fracture location                  | Medical Cost (SNT), mean, (S.D.) | Length of Stay (days), mean, (S.D.) |
|-----------------------------------|----------------------------------|----------------------------------|
|                                   | In general                       | Female                          | Male                          |
|                                   | cases   | mean (S.D.) | cases   | mean (S.D.) | cases   | mean (S.D.) | cases   | mean (S.D.) | cases   | mean (S.D.) | cases   | mean (S.D.) | cases   | mean (S.D.) | cases   | mean (S.D.) | cases   | mean (S.D.) |
| Pathological Fx of Humerus        | 154     | 353,575   | 407,372 | 76       | 360,005   | 346,344 | 78       | 347,309   | 461,335 | 0.357    | 154     | 43.9      | 42.9     | 76       | 48.3      | 45.7     | 78       | 39.6      | 39.8     | 0.402    |
| Pathological Fx of Distal Radius/Ulna | 18      | 293,803   | 387,673 | 11       | 178,740   | 210,325 | 7        | 474,616   | 538,219 | 0.009    | 18      | 31.1      | 32.9     | 11       | 21.0      | 19.0     | 7        | 47.0      | 44.5     | 0.020    |
| Pathological Fx of Vertebrae      | 2424    | 200,015   | 256,668 | 1,451    | 186,175   | 245,394 | 973      | 220,654   | 271,435 | 0.005    | 2424    | 29.4      | 34.4     | 1,451    | 26.3      | 30.3     | 973      | 33.9      | 39.4     | 0.000    |
| Pathological Fx of Neck of Femur  | 254     | 307,807   | 284,991 | 139      | 303,879   | 248,781 | 115      | 312,555   | 324,480 | 0.324    | 254     | 43.3      | 41.2     | 139      | 45.7      | 42.7     | 115      | 40.4      | 39.5     | 0.327    |
| Pathological Fx of Other Part of Femur | 128    | 340,675   | 352,755 | 69       | 350,874   | 394,534 | 59       | 328,747   | 299,516 | 0.270    | 128     | 42.4      | 38.1     | 69       | 43.5      | 42.4     | 59       | 41.3      | 32.7     | 0.165    |
| Pathological Fx of Tibia and Fibula | 25     | 300,888   | 316,227 | 11       | 290,137   | 309,024 | 14       | 309,335   | 333,140 | 0.451    | 25      | 42.0      | 32.8     | 11       | 43.6      | 26.5     | 14       | 40.6      | 38.0     | 0.119    |

S.D.: standard deviation

*Descriptive comparison of differences between genders was performed by the independent t-test.
Few studies of the medical burden of bone metastatic disease or pathologic fractures have been performed, but the cost of bone metastasis in cancer patients was estimated to be $12.6 billion dollars per year (17% of the total direct medical cost) in the US from 2000 to 2004 [7]. In the Netherlands, a retrospective cost analysis study associated with bone metastases in patients with prostate cancer showed an average cost of 6,973 Euros per patient to treat skeletal-related events [10]. We calculated in this study the mean direct medical cost and administrative utilization for individual pathologic fracture cases in Taiwan, to compare with individual non-pathologic fracture cases in Taiwan according to Taiwan Diagnoses Related Groups (TW-DRGs), the new payment regulations in Taiwan that have been in place since January 1st 2010. For example, a lower-extremity (excepting the femur) or humeral fracture can be paid US$583-3,109, with an average of 6-8 days in hospital being allowed, and for a hip or femoral fracture, the cost is US$952-3,691, with an average stay of 7-10 days [11]. These values are much lower than those estimated in the present study. However, owing to the scarcity of published literature on this topic, we were not able to adequately compare Taiwanese expenditures against expenditures of other nations, for bone metastasis or for the costs of follow-up treatment for metastatic bony events. Future studies concerning medical economic issues should be encouraged in order to assist public health policymakers in making policy decisions worldwide.

Several decades ago, more conservative treatments for pathologic fractures were accepted. A study evaluating the results of treating seventy-two pathologic long-bone fractures revealed that only 25% of upper-extremity and 57.5% of lower-extremity pathologic fractures were treated with internal fixation, and better outcomes were noted for those treated by internal fixation than those treated by other means [12]. Recently, surgical treatment has been employed for impending or existing pathologic fractures. In a recent prospective study based upon the skeletal metastasis register of the Scandinavian Sarcoma Group, pathologic fracture was found to be an independent negative prognostic factor of one-year survival [13]. Another recent study showed that of 2,776 patients with intracapsular fractures of the proximal femur, 18% of patients were treated non-surgically. Included in the group of patients who were treated conservatively were children, patients with cardiac problems, mental problems, stroke, renal failure, and multiple disseminated malignancies, and patients who chose non-surgical treatment [14]. In comparison with the proportions of cases in which surgical intervention was performed reported in the above-mentioned studies, the surgical rate for pathologic fracture in Taiwan was found in this study to be on a par with that reported for other countries for the upper limbs but lower for the lower limbs. This study took a nationwide overview of pathologic fractures registered in the health insurance inpatient database rather than examining the outcomes of patients referred to hospital for treatment in Taiwan. More conservative treatment in some community hospitals and less adequate referral processes to tertiary treatment centres are possible causes of this difference, and further studies should be performed in the future to investigate this issue.

There were some principal limitations in the present study. This was a one-year cross sectional study investigating the characteristics of pathological fractures requiring hospitalization based on the NHI dataset.

### Table 3 Distribution of surgical intervention for pathologic fractures of an identifiable location in Taiwan, 2008 (valid n = 3003)

| Bony surgery performed? | Pathologic Fx of Humerus (n = 154) | Pathologic Fx of Distal Radius/Ulna (n = 18) | Pathologic Fx of Vertebrae (n = 2424) | Pathologic Fx of Neck of Femur (n = 254) | Pathologic Fx of Other Part of Femur (n = 128) | Pathologic Fx of Tibia and Fibula (n = 25) |
|-------------------------|-----------------------------------|------------------------------------------|-------------------------------------|----------------------------------------|---------------------------------------------|-----------------------------------------|
| Yes                     | 48 (31.2%)                        | 8 (44.4%)                                | 273 (11.3%)                         | 118 (46.5%)                            | 62 (48.4%)                                  | 13 (52.0%)                              |
| No                      | 106 (69.8%)                       | 10 (55.6%)                               | 2151 (88.7%)                       | 136 (53.5%)                            | 66 (51.6%)                                  | 12 (48.0%)                              |

Bony surgery strategy:

1. Instrument fixation
   - Yes: 41 (91%)
   - No: 9 (7.8%)

2. Spine fusion
   - Yes: 58 (91.0%)
   - No: 52 (10.5%)

3. Prosthesis
   - No: 3 (100%)

4. Excision, biopsy
   - No: 164 (100%)

5. Bone-grafting, bone plastic
   - No: 28 (100%)

Note: There were no statistically significant differences between genders, for bony surgery rates, tested separately for each fracture category.

*Anterior fusion procedures
**Posterior-lateral fusion procedures
Claims data are not linked to the death register data bank in Taiwan; therefore, prospective survival analysis for subsequent events, including complications of surgery or death, was not able to be performed. Further information and investigations are needed in the future.

Conclusion
We observed in our study that medical utilization for pathologic fracture cases was higher in Taiwan compared to that reported for other nations. However, we also noted less-aggressive surgical intervention for patients hospitalized with pathologic fractures in Taiwan in comparison with other countries.

Acknowledgements
This study was supported by a grant from Taoyuan General Hospital, Department of Health, Executive Yuan, Taiwan (PTH-9910) and partially supported by the project "NSC 99-2221-E-155-045-MY3".

Authors' contributions
The study was designed by YHL, CLC and NPY; data were gathered and analysed by YF, DVP and NPY; the initial draft of the manuscript was written by YHL, YNH and NPY; and the accuracy of the data and analyses was assured by PC, CLC and NPY. All authors participated in the preparation of the manuscript and approved the final version.

Competing interests
This study was funded by Taoyuan General Hospital, Department of Health, Executive Yuan, Taiwan only. All authors declare that they have no conflicts of interest, including directorships, stock holdings or contracts.

Received: 22 October 2010 Accepted: 22 September 2011
Published: 22 September 2011

References
1. Varadhanichay GR, Abbuzzese JL, Lenzi R. Diagnostic Strategies for Unknown Primary Cancer. Cancer 2004, 100:1766-1185.
2. Biermann JS, Holt GE, Lewis VO, Schwartz HS, Yaszemski MJ. Metastatic Bone Disease: Diagnosis, Evaluation, and Treatment. J Bone Joint Surg Am 2009, 91:1518-1530.
3. Bickels J, Dadia S, Lidal Z. Current Concepts Review: Surgical Management of Metastatic Bone Disease. J Bone Joint Surg Am 2009, 91:1503-1516.
4. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine 2001, 26:298-306.
5. Swanson KC, Pritchard DJ, Franklin H, Sim FH. Surgical Treatment of Metastatic Disease of the Femur. J Am Acad Orthop Surg 2000, 8:56-65.
6. Rodman GD. Mechanism of bone metastasis. N Engl J Med 2004, 350:1655-1664.
7. Schulman KL, Kohles J. Economic Burden of Metastatic Bone Disease in the U.S. Cancer 2007, 109:2334-2342.
8. Ekholm R, Adami J, Tidermark J, Hansson K, Tomkivt H, Ponzer S. Fractures of the Shaft of the Humerus: An Epidemiological Study of 401 Fractures. J Bone Joint Surg Br 2006, 88:1469-1473.
9. Toma CD, Dominikus M, Nidelcu T, Abdohahab F, Assadian O, Krepler P, Kort R. Metastatic Bone Disease: A 36-year Single Centre Trend-analysis of Patients Admitted to a Tertiary Orthopaedic Surgical Department. J Surg Oncol 2007, 96:404-410.
10. Groot MT, Boeken Kuyper CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003, 43:226-232.
11. National Health Insurance Bureau 652 Documents related to TW-DRGs. [http://www.nhi.gov.tw/Search/Search.aspx?qwords=DRG], Accessed September 7, 2011.
12. Douglass HO, Shukla SK, Mindell E. Treatment of pathological fractures of long bones excluding those due to breast cancer. J Bone Joint Surg Am 1976, 58:1055-1061.
13. Hansen BH, Keller J, Laitinen M, Berg P, Skjeldal S, Trovik C, Nilsson J, Wallow A, Kalen A, Wedin R. The Scandinavian Sarcoma Group Skeletal Metastasis Register. Survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop Scand Suppl 2004, 75:11-15.
14. Heim M, Adunski A, Chechick A. Nonoperative treatment of intracapsular fractures of the proximal femur. Clin Orthop Relat Res 2002, 399:35-41.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1472-6963/11/230/prepub

Cite this article as: Lee et al. Treatment incidence of and medical utilization for hospitalized subjects with pathologic fractures in Taiwan-Survey of the 2008 National Health Insurance data. BMC Health Services Research 2011 11:230

doi:10.1186/1472-6963-11-230

Submit your next manuscript to BioMed Central and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit